Better to be snowed under by actual snow than pretty much anything else, we suppose. Here are a few other flakes that accumulated over the weekend ...
- Not everyone is happy with Shire's managment manouevrings. The Financial Times points out that the Association of British Insurers suggests its members, which the hold roughly one fifth of the equity, might press for a more detailed explanation of Matt Emmens' move from CEO to chairman.
- Highlights from the San Antonio Breast Cancer Symposium: GSK presented Phase II results suggesting Tykerb may be beneficial as part of combination therapy in breast cancer that has spread to the brain. Amgen's osteoporosis drug denosumab increases bone strength in patients receiving hormone therapy for breast cancer, the company reported. Genomic Health said it has confirmed the efficacy of its Oncotype Dx test in predicting breast cancer recurrence. Regenerative medicine company Cytori reported positive preclinical and clinical results from studies of its adipose-derived stem cell platform, in fat graft retention and breaset reconstruction, respectively.
- Intrigue at UCSF medical school. Bloomberg News is reporting that former FDA commish David Kessler says he was fired from the school's top post on Friday for pointing out financial irregularities. One hundred million dollar financial irregularities Hat Tip: Pharmalot.
- Hello, Santa!
No comments:
Post a Comment